Article Information
History
- May 11, 2020.
Article Versions
- You are currently viewing Version 1 of this article (May 11, 2020 - 06:06).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Benjamin Davido1,§,*,
- Thibaud Lansaman2,
- Simon Bessis1,
- Christine Lawrence3,
- Jean-Claude Alvarez4,
- Hélène Mascitti1,
- Frédérique Bouchand5,
- Pierre Moine6,
- Véronique Perronne1,
- Aurélie Le Gal1,
- Djillali Annane6,
- Christian Perronne1,
- Pierre De Truchis1,§ and
- on behalf of the COVID-19 RPC Team
- 1Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France
- 2Rééducation fonctionnelle, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France
- 3EOH, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France
- 4Pharmaco-toxicologie, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France
- 5Pharmacie Hospitalière, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France
- 6Réanimation médicale, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France
- ↵*Corresponding author:
Benjamin Davido, Service de Maladies Infectieuses et Tropicales, Hôpital Raymond-Poincaré, Garches 92380, France., Tel: +33-1-47107758, e-mail: benjamin.davido{at}aphp.fr
↵§ Both authors contributed equally to this work.
Posted May 11, 2020.
Hydroxychloroquine plus azithromycin: a potential interest in reducing in-hospital morbidity due to COVID-19 pneumonia (HI-ZY-COVID)?
